Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.

@article{Tong2010ImatinibFT,
  title={Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.},
  author={Weichao Tong and Hagop M Kantarjian and Susan M O'Brien and Stefan H. Faderl and Farhad Ravandi and Gautam Borthakur and Jianqin Shan and Sherry A. Pierce and Mary Beth Rios and Jorge E Cortes},
  journal={Cancer},
  year={2010},
  volume={116 13},
  pages={
          3152-9
        }
}
BACKGROUND Imatinib 400 mg daily is the standard treatment for patients with chronic myelogenous leukemia (CML). The safety and efficacy of imatinib in CML patients with pre-existing liver and/or renal dysfunction has not been analyzed. METHODS The authors analyzed the outcome of 259 patients with early chronic phase CML treated with imatinib (starting dose 400 mg in 50, 800 mg in 209). Pre-existing liver and/or renal dysfunction was seen in 38 (15%) and 11 (4%) patients, respectively… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

Similar Papers

Loading similar papers…